D037: ACLY as a therapeutic target to promote T cell-driven antitumor immune response in IBD-associated colon cancer

FAU own research funding: EFI / IZKF / EAM ...


Start date : 01.04.2023

End date : 30.09.2025

Project details

Scientific Abstract

Our preliminary data indicate a beneficial role of the metabolic enzyme ACLY in T cells in the AOM/DSS-induced CAC (colitis-associated cancer) model, while published data implicate that upregulation of ACLY in colon tumor cells promotes metastasis. Thus, we aim on the development of clinically applicable strategies to trigger ACLY activity selectively in tumor-infiltrating T cells and will focus on the identification of those CAC patients, who could best benefit from an ACLY-targeting therapy.

Involved:

Imke Atreya Project Leader Elisabeth Naschberger Project Member Raja Atreya Project Member Arne Geßner Project Member

Contributing FAU Organisations:

Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Department of Surgery

Funding Source

Mittelgeber / Förderprogramme